Salarius Pharmaceuticals, Inc.

NASDAQ (USD): Salarius Pharmaceuticals, Inc. (SLRX)

Last Price

1.55

Today's Change

+0.14 (9.92%)

Day's Change

1.28 - 1.60

Trading Volume

321,551

Overview

Market Cap

2 Million

Shares Outstanding

1 Million

Avg Volume

324,636

Avg Price (50 Days)

1.52

Avg Price (200 Days)

2.61

PE Ratio

-0.30

EPS

-5.14

Earnings Announcement

20-Mar-2025

Previous Close

1.41

Open

1.41

Day's Range

1.28 - 1.6

Year Range

1.22 - 7.2

Trading Volume

321,201

Price Change Highlight

1 Day Change

9.93%

5 Day Change

5.44%

1 Month Change

6.16%

3 Month Change

-9.36%

6 Month Change

-38.49%

Ytd Change

-69.73%

1 Year Change

-66.95%

3 Year Change

-98.53%

5 Year Change

-99.81%

10 Year Change

-100.00%

Max Change

-100.00%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment